The efficacy of piperacillin/tazobactam in experimental Pseudomonas Aeruginosa endophthalmitis: A histopathological and microbiological evaluation

Current Eye Research

Volumn 30, Issue 1, 2005, Pages 13-19

  Özkiris, Abdullah ^a,b   Evereklioglu, Cem ^a   Esel, Duygu ^a   Akgün, Hülya ^a   Göktas, Sertan ^a   Erkiliç, Kuddusi ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b Yildirim Beyazit Mah Mustafa Simsek   (Turkey)

Author keywords

Histopathological and microbiological evaluation; Intravitreal piperacillin tazobactam; P. aeruginosa endophthalmitis

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EXAMINATION; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ENDOPHTHALMITIS; ENUCLEATION; HISTOPATHOLOGY; INOCULATION; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RABBIT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; MALE; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; TREATMENT OUTCOME; VITREOUS BODY;

EID: 14744273362     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680490894180     Document Type: Article

References (32)

1. Endophthalmitis Vitrectomy Study Group. Results of the endophthalmitis vitrectomy study. Arch Ophthalmol. 1995;113:1479-1496.
2. Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology. 1998;105:1004-1010.
3. Kielhofner M, Atmar RL, Hamill RJ, Musher DM. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect Dis. 1992;14:403-411.
4. Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bacterial endophthalmitis: A 17-year prospective series and review of 267 reported cases. Surv Ophthalmol. 2003;48:403-423.
5. Irvine WD, Flynn HW Jr, Miller D, Pflugfelder SC. Endophthalmitis caused by gram-negative organisms. Arch Ophthalmol. 1992;110:1450-1454.
6. Cunha BA. Pseudomonas aeruginosa: Resistance and therapy. Semin Respir Infect. 2002;17:231-239.
7. Korvick JA, Yu VL. Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991;35:2167-2172.
8. Bryson HM, Brogden RN. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1994;47:506-535.
9. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, Maravi-Poma E, Torres-Marti A, Nava J, Martinez-Pellus A, Palomar M, Barcenilla F. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: A prospective randomized multicenter trial. Intensive Care Med. 2001;27:493-502.
10. Niinikoski J, Havia T, Alhava E, Paakkonen M, Miettinen P, Kivilaakso E, Haapiainen R, Matikainen M, Laitinen S. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet. 1993;176:255-261.
11. Özkiriş A, Evereklioglu C, Kontaş O, Öner A, Erkiliç K. Determination of non-toxic concentrations of piperacillin/tazobactam for intravitreal application: An electroretinographic, histopathologic and morphometric analysis. Ophthalmic Res. 2004;36:139-144.
12. Evereklioglu C, Sari I, Alasehirli B, Guldur E, Cengiz B, Balat O, Bagci C. High dose of maternal caffeine administred to pregnant rats causes histopathological changes in the cornea of newborn pups. Med Sci Monitor. 2003;9:168-173.
13. Hindler J. Antimicrobial susceptibility testing. In: Isenberg HD. Essential procedures for Clinical Microbiology. Washington: American Society for Microbiology; 1998:205-215.
14. Evereklioglu C, Özkiriş A, Alasehirli B, Sari I, Guldur E, Cengiz B, Kontas O. Effect of gestational nicotine treatment on newborn rat retina: A histopathological and morphometric analysis. Ophthalmic Physiol Opt. 2003;23:527-533.
15. Kim IT, Park SK, Lim JH. Inflammatory response in experimental Staphylococcus and Pseudomonas endophthalmitis. Ophthalmologica. 1999;213:305-310.
16. Ryan EH, Mizener JB. Tissue plasminogen activator and Staphylococcus epidermidis endophthalmitis. Arch Ophthalmol. 1993;111:1117-1122.
17. Meredith TA, Trabelsi A, Miller MJ, Aguilar E, Wilson LA. Spontaneous sterilization in experimental Staphylococcus epidermidis endophthalmitis. Invest Ophthalmol Vis Sci. 1990;31:181-186.
18. Coudron P, Jones DL, Dalton HP, Archer GL. Evaluation of laboratory tests for detection of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. J Clin Microbiol. 1986;24:764-769.
19. Reedy JS, Wood KE. Endogenous Pseudomonas aeruginosa endophthalmitis: A case report and literature review. Intensive Care Med. 2000;26:1386-1339.
20. Zaluski S, Clayman HM, Karsenti G, Bourzeix S, Tournemire A, Faliu B, Gulian C, Grimont F. Pseudomonas aeruginosa endophthalmitis caused by contamination of the internal fluid pathways of a phacoemulsifier. J Cataract Refract Surg. 1999;25:540-545.
21. Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol. 1996;122:830-846.
22. Eifrig CW, Scott IU, Flynn HW Jr, Miller D. Endophthalmitis caused by Pseudomonas aeruginosa. Ophthalmology. 2003;110:1714-1717.
23. Anand AR, Therese KL, Madhavan HN. Spectrum of aetiological agents of postoperative endophthalmitis and antibiotic susceptibility of bacterial isolates. Indian J Ophthalmol. 2000;48:123-128.
24. Liang C, Peyman GA, Molinari LC, Hegazy HM. Prophylaxis of experimental Pseudomonas aeruginosa endophthalmitis after vitrectomy using ceftazidime in the irrigating solution. Int Ophthalmol. 1998;22:163-167.
25. Alfaro DV 3rd, Hudson SJ, Kasowski EJ, Barton CP, Brucker AJ, Lopez JD, Beverly DT, King LP. Experimental pseudomonal posttraumatic endophthalmitis in a swine model. Treatment with ceftazidime, amikacin, and imipenem. Retina. 1997;17:139-145.
26. Perry CM, Markham A. Piperacillin/tazobactam: An updated review of its use in the treatment of bacterial infections. Drugs. 1999;57:805-843.
27. Bourget P, Lesne-Hulin A, Le Reveille R, Le Bever H, Carsin H. Clinical pharmacokinetics of piperacillintazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother. 1996;40:139-145.
28. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillintazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum betalactamases: Report from the ARREST Program. Antimicrob Agents Chemother. 2003;47:1643-1646.
29. Bellais S, Mimoz O, Leotard S, Jacolot A, Petitjean O, Nordmann P. Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46:2032-2034.
30. Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. Chemotherapy. 2002;48:59-63.
31. Jiraskova N, Rozsival P. Delayed-onset Pseudomonas stutzeri endophthalmitis after uncomplicated cataract surgery. J Cataract Refract Surg. 1998;24:866-867.
32. Del Piero E, Pennett M, Leopold I. Pseudomonas cepacia endophthalmitis. Ann Ophthalmol. 1985;17:753-756.